Investor Relations

The institutional opportunity.

SQT is in active discussion with qualified U.S. SPAC sponsors and anchor PIPE investors for a proposed business combination of USD 175–250M gross raise, targeting listing on NYSE or Nasdaq. The materials below summarize the transaction, valuation framework, and use of proceeds. Full diligence materials available under NDA.

Transaction Structure

At a glance.

Combined Raise · Gross
$175–250M
SPAC trust + PIPE. Base case $175M, upside to $250M on anchor commitments.
Pre-Money Equity · Base
$80M
Triangulated across four methodologies. Central range $50–80M; upside $150M post-milestone.
Pro-Forma Enterprise Value
~$255M
Post-closing base case. Conservative ~$175M; upside ~$400M.
Metric Conservative Base Case Upside
Pre-Money Equity Value $50M $80M $150M
SPAC Trust $75M $100M $150M
PIPE Investment $50M $75M $100M
Combined Raise (Gross) $125M $175M $250M
Net Proceeds (Est.) $100M $150M $220M
Pro-Forma Enterprise Value ~$175M ~$255M ~$400M

Net proceeds assume a 30% SPAC redemption scenario and approximately $25M of transaction and advisory expenses. Upside scenario pre-money is anchored to post-commercialization-milestone valuation. Illustrative only — subject to market conditions and definitive transaction documentation.

Target Sponsor Profile

The partner we're looking for.

01 / PIPE CAPACITY

Institutional syndication depth.

Demonstrated institutional PIPE syndication capability, ideally with committed lead-investor capacity of USD 25M+ and track record of closing deals in current-vintage market conditions.

02 / CROSS-BORDER

U.S.–Europe listing experience.

Familiar with cross-border transaction structures, Swiss corporate law interaction with U.S. public company regimes, and deep-tech infrastructure business economics.

03 / TRUST SCALE

Residual trust $75–150M net of redemptions.

Trust size appropriate to the $125–250M combined raise — with redemption-backstop mechanics and minimum-cash-condition protections already contemplated in the structure.

04 / LONG-TERM

Follow-on capacity for scale rounds.

Capital markets partner profile supporting long-term shareholder value creation beyond closing — including follow-on equity capacity for post-commercialization scale-up rounds.

Valuation Framework

Four methodologies.
One triangulated range.

Management and its advisors triangulate fair equity value across four independent methodologies — comparable companies, risk-adjusted DCF, real options on the D-Wave contract, and adjusted NAV. The resulting central range of $50–80M supports the base case pre-money.

Methodology Weight Conservative Central Upside
Comparable Companies 35% ~$20M ~$60M ~$150M
Risk-Adjusted DCF 30% ~$15M ~$30M ~$50M
Real Options (D-Wave) 25% ~$20M ~$45M ~$80M
Net Asset Value · adjusted Floor ~$0M ~$1M ~$2M
Weighted Triangulation 100% $15M $50–80M $150M
COMPARABLE COMPANIES

European Series A deep-tech quantum band: $30–80M.

Anchored to Pasqal (Series B, 2024), IQM (Series A, 2022–2023), Alice & Bob (Series B, 2024), ORCA Computing, and Terra Quantum. Pre-revenue Series A quantum peers trade in $30–80M pre-money, with standout IP or anchor-customer profiles extending to $150M. SQT's executed D-Wave contract supports mid-to-upper-range positioning.

RISK-ADJUSTED DCF

Probability-weighted to $30M central.

Applies 25% cost of equity across five scenarios: full success (10%), partial success (25%), minimal traction (25%), commercial failure (30%), insolvency (10%). Probability-weighted equity value ~$60M at maturity, discounted to $30M central with a range of $15–50M.

REAL OPTIONS · D-WAVE

$45M central on the option structure alone.

The D-Wave Agreement is economically equivalent to a 5-year compound call option on industrial quantum annealing commercialization. Black-Scholes-Merton with 60–80% volatility and $60–150M underlying asset value produces option values of $20M (conservative) to $80M (upside), central $45M.

NET ASSET VALUE

Floor near zero — reinforcing the thesis.

Book NAV is negative; adjusted NAV including shell value and platform replacement cost yields ~$0–2M floor. The methodology confirms that essentially all positive fair value derives from the strategic asset position — the D-Wave contract and Portfolio CH platform — not historical operating performance.

Financial Projections

Commercialization to scale.
2026 → 2030.

Management's base case forecast. 2026–2027 is the commercialization phase — capability buildout, team hiring, first institutional pilots. 2028 is the EBITDA crossover inflection. 2029–2030 is the scale phase driven by multi-vertical traction.

Metric · $M 2026E 2027E 2028E 2029E 2030E
Revenue 2 8 22 50 100
YoY Growth 300% 175% 127% 100%
Gross Margin ~55% ~65% ~72% ~78% ~80%
EBITDA (10) (5) 2 15 40
EBITDA Margin n.m. n.m. ~9% 30% 40%
Capex ~2 ~3 ~3 ~4 ~5
Free Cash Flow (12) (8) (1) 11 35

Forward-looking. Projections reflect management's central estimates as of April 2026, anchored in the D-Wave Hosted System Agreement and current commercial pipeline. Not guarantees of future performance. Subject to risks described in the institutional memorandum.

Use of Proceeds

Where $150M base case goes.

Disciplined capital deployment sized against the 2026–2030 commercialization plan. Fully funds the €10M D-Wave obligation, reserves the €25M purchase option, and underwrites the commercial buildout through positive cash flow.

Category Allocation · $M % of Net Purpose
D-Wave Contract Obligations · 5yr $55M 37% Full €10M commitment over 5-year term
D-Wave Purchase Option · €25M $28M 19% Reserved for event-driven exercise ~2028–2029
Platform Engineering & IP $20M 13% Core engineering, proprietary IP, enterprise APIs
Commercial Buildout & Sales $15M 10% Enterprise sales, institutional partnerships, pilots
Team Buildout · 25–50 FTE $15M 10% Engineering, data science, commercial over 24 months
Public Company Operating Base $10M 7% Finance, legal, compliance, audit, IR
Strategic Reserve $7M 5% Contingency & opportunistic M&A
Process & Timeline

From first meeting to listing.

Management is available for immediate engagement with qualified SPAC sponsors, lead PIPE investors, and their advisors. Indicative timeline assumes a constructive diligence process and customary transaction milestones.

Weeks 1–2

Preliminary Discussions & NDA

Initial sponsor meetings. NDA execution. Preliminary financial data room access. Qualitative assessment of sponsor-company fit.

Weeks 3–8

Mutual Diligence & Letter of Intent

Commercial, technical, and legal due diligence. D-Wave contract review. Draft Letter of Intent. Indicative valuation alignment.

Weeks 9–18

Definitive Agreement

Business Combination Agreement negotiation. PIPE anchor commitments. Transaction support mechanics (NRA/FPA). SPAC trust structuring.

Weeks 19–36

S-4 / Proxy & Marketing

SEC registration statement filing. Analyst and investor roadshow. Shareholder proxy vote. PIPE closing.

Weeks 37–40

Closing & Public Listing

De-SPAC closing. NYSE or Nasdaq listing. Post-closing execution kick-off.

Next Step

Request the institutional data room.

Full diligence materials — including the executed D-Wave Hosted System Agreement, independent valuation report, financial model, and commercial pipeline detail — are released to qualified parties under NDA.

Contact Investor Relations Technology Overview

This page does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. Any such offer or solicitation will be made only by means of definitive transaction documentation and a registration statement and/or proxy statement filed with the U.S. Securities and Exchange Commission or equivalent regulator and delivered to eligible recipients in accordance with applicable law. Forward-looking statements are subject to significant risks, uncertainties, and factors. Actual results may differ materially from those expressed or implied. No representation or warranty, express or implied, is made as to the accuracy or completeness of the information contained herein.